Baidu
map

European Radiology:CTA与Agatston评分对冠心病稳定胸痛患者的诊断价值

2022-07-07 shaosai MedSci原创

众所周知,CTA 在检测稳定性胸痛患者的阻塞性 CAD 方面显示出良好的诊断准确性。

冠状动脉钙(CAC)已成为检测冠状动脉疾病(CAD)严重程度的独立诊断指标,最常用的量化方法是Agatston评分法,CAC定量评估常用于无症状患者的风险分层。

CORE-64国际多中心研究显示,CTA对CAC升高超过600的患者的诊断准确性明显降低。众所周知,CTA 在检测稳定性胸痛患者的阻塞性 CAD 方面显示出良好的诊断准确性。由于 Agatston 评分与 CTA 的比较诊断准确性存在相互矛盾,因此Agatston 评分在检测阻塞性 CAD 中的诊断仍不明确

近日,发表在European Radiology杂志的一项研究通过使用来自全球协作性COME-CCT联盟分析,进一步明确了 CTA 的诊断准确性是否受到较高 Agatston 评分的影响,为对冠心病患者进行准确的风险分层提供了参考依据。

析(COME-CCT)联盟共纳入了2452名有稳定胸痛并有临床指征的疑似CAD的侵入性冠状动脉造影(ICA)患者。Agatston评分>400被认为是阳性,阻塞性CAD被定义为ICA上冠状动脉直径狭窄至少50%,被用作参考标准。 

44.9%的患者(1100/2452)被诊断为阻塞性CAD。Agatston评分的中位数为74。CTA检测阻塞性CAD的诊断准确性(81.1%,95%置信区间[CI]:77.5至84.1%)明显高于Agatston评分(68.8%,95%CI:64.2至73.1%,P <0.001)。在Agatston评分为零的患者中,17%(101/600)有阻塞性CAD。CTA的诊断准确性在低至中度(1至<100,100-400)与中至高度Agatston评分(401-1000,>1000)的患者中没有明显差异。 


 CTA和Agatston评分的SROC曲线

与Agatston评分相比,CTA在检测有稳定胸痛并有ICA临床指征的有症状患者的CAD方面显示出总体上更高的诊断准确性。这些发现适用于不同Agatston评分的患者,包括没有冠状动脉钙化的患者。此外,CTA的诊断准确性在中、高度Agatston评分的患者中诊断性能一致。

原文出处:

Viktoria Wieske,Mario Walther,Benjamin Dubourg,et al.Computed tomography angiography versus Agatston score for diagnosis of coronary artery disease in patients with stable chest pain: individual patient data meta-analysis of the international COME-CCT Consortium.DOI:10.1007/s00330-022-08619-4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2062381, encodeId=e1c12062381a3, content=<a href='/topic/show?id=2198208e64' target=_blank style='color:#2F92EE;'>#AGA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2087, encryptionId=2198208e64, topicName=AGA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Thu Feb 16 01:32:14 CST 2023, time=2023-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729654, encodeId=10f71e2965406, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jun 12 08:32:14 CST 2023, time=2023-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850173, encodeId=cc1218501e30b, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Aug 21 04:32:14 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721702, encodeId=78fa1e217025e, content=<a href='/topic/show?id=39d6915e9bf' target=_blank style='color:#2F92EE;'>#诊断价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91579, encryptionId=39d6915e9bf, topicName=诊断价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c7d33065043, createdName=medscijoin, createdTime=Tue Aug 23 19:32:14 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068268, encodeId=c77320682680d, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Dec 13 09:32:14 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605349, encodeId=27e51605349c3, content=<a href='/topic/show?id=b94d1e90023' target=_blank style='color:#2F92EE;'>#TST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17900, encryptionId=b94d1e90023, topicName=TST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30e219383639, createdName=ms3153534357578991, createdTime=Thu Jul 07 02:32:14 CST 2022, time=2022-07-07, status=1, ipAttribution=)]
    2023-02-16 vera_1203
  2. [GetPortalCommentsPageByObjectIdResponse(id=2062381, encodeId=e1c12062381a3, content=<a href='/topic/show?id=2198208e64' target=_blank style='color:#2F92EE;'>#AGA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2087, encryptionId=2198208e64, topicName=AGA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Thu Feb 16 01:32:14 CST 2023, time=2023-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729654, encodeId=10f71e2965406, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jun 12 08:32:14 CST 2023, time=2023-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850173, encodeId=cc1218501e30b, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Aug 21 04:32:14 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721702, encodeId=78fa1e217025e, content=<a href='/topic/show?id=39d6915e9bf' target=_blank style='color:#2F92EE;'>#诊断价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91579, encryptionId=39d6915e9bf, topicName=诊断价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c7d33065043, createdName=medscijoin, createdTime=Tue Aug 23 19:32:14 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068268, encodeId=c77320682680d, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Dec 13 09:32:14 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605349, encodeId=27e51605349c3, content=<a href='/topic/show?id=b94d1e90023' target=_blank style='color:#2F92EE;'>#TST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17900, encryptionId=b94d1e90023, topicName=TST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30e219383639, createdName=ms3153534357578991, createdTime=Thu Jul 07 02:32:14 CST 2022, time=2022-07-07, status=1, ipAttribution=)]
    2023-06-12 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=2062381, encodeId=e1c12062381a3, content=<a href='/topic/show?id=2198208e64' target=_blank style='color:#2F92EE;'>#AGA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2087, encryptionId=2198208e64, topicName=AGA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Thu Feb 16 01:32:14 CST 2023, time=2023-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729654, encodeId=10f71e2965406, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jun 12 08:32:14 CST 2023, time=2023-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850173, encodeId=cc1218501e30b, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Aug 21 04:32:14 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721702, encodeId=78fa1e217025e, content=<a href='/topic/show?id=39d6915e9bf' target=_blank style='color:#2F92EE;'>#诊断价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91579, encryptionId=39d6915e9bf, topicName=诊断价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c7d33065043, createdName=medscijoin, createdTime=Tue Aug 23 19:32:14 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068268, encodeId=c77320682680d, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Dec 13 09:32:14 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605349, encodeId=27e51605349c3, content=<a href='/topic/show?id=b94d1e90023' target=_blank style='color:#2F92EE;'>#TST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17900, encryptionId=b94d1e90023, topicName=TST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30e219383639, createdName=ms3153534357578991, createdTime=Thu Jul 07 02:32:14 CST 2022, time=2022-07-07, status=1, ipAttribution=)]
    2022-08-21 windight
  4. [GetPortalCommentsPageByObjectIdResponse(id=2062381, encodeId=e1c12062381a3, content=<a href='/topic/show?id=2198208e64' target=_blank style='color:#2F92EE;'>#AGA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2087, encryptionId=2198208e64, topicName=AGA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Thu Feb 16 01:32:14 CST 2023, time=2023-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729654, encodeId=10f71e2965406, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jun 12 08:32:14 CST 2023, time=2023-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850173, encodeId=cc1218501e30b, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Aug 21 04:32:14 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721702, encodeId=78fa1e217025e, content=<a href='/topic/show?id=39d6915e9bf' target=_blank style='color:#2F92EE;'>#诊断价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91579, encryptionId=39d6915e9bf, topicName=诊断价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c7d33065043, createdName=medscijoin, createdTime=Tue Aug 23 19:32:14 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068268, encodeId=c77320682680d, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Dec 13 09:32:14 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605349, encodeId=27e51605349c3, content=<a href='/topic/show?id=b94d1e90023' target=_blank style='color:#2F92EE;'>#TST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17900, encryptionId=b94d1e90023, topicName=TST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30e219383639, createdName=ms3153534357578991, createdTime=Thu Jul 07 02:32:14 CST 2022, time=2022-07-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2062381, encodeId=e1c12062381a3, content=<a href='/topic/show?id=2198208e64' target=_blank style='color:#2F92EE;'>#AGA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2087, encryptionId=2198208e64, topicName=AGA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Thu Feb 16 01:32:14 CST 2023, time=2023-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729654, encodeId=10f71e2965406, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jun 12 08:32:14 CST 2023, time=2023-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850173, encodeId=cc1218501e30b, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Aug 21 04:32:14 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721702, encodeId=78fa1e217025e, content=<a href='/topic/show?id=39d6915e9bf' target=_blank style='color:#2F92EE;'>#诊断价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91579, encryptionId=39d6915e9bf, topicName=诊断价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c7d33065043, createdName=medscijoin, createdTime=Tue Aug 23 19:32:14 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068268, encodeId=c77320682680d, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Dec 13 09:32:14 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605349, encodeId=27e51605349c3, content=<a href='/topic/show?id=b94d1e90023' target=_blank style='color:#2F92EE;'>#TST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17900, encryptionId=b94d1e90023, topicName=TST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30e219383639, createdName=ms3153534357578991, createdTime=Thu Jul 07 02:32:14 CST 2022, time=2022-07-07, status=1, ipAttribution=)]
    2022-12-13 一叶知秋
  6. [GetPortalCommentsPageByObjectIdResponse(id=2062381, encodeId=e1c12062381a3, content=<a href='/topic/show?id=2198208e64' target=_blank style='color:#2F92EE;'>#AGA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2087, encryptionId=2198208e64, topicName=AGA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Thu Feb 16 01:32:14 CST 2023, time=2023-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729654, encodeId=10f71e2965406, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jun 12 08:32:14 CST 2023, time=2023-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1850173, encodeId=cc1218501e30b, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Aug 21 04:32:14 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721702, encodeId=78fa1e217025e, content=<a href='/topic/show?id=39d6915e9bf' target=_blank style='color:#2F92EE;'>#诊断价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91579, encryptionId=39d6915e9bf, topicName=诊断价值)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c7d33065043, createdName=medscijoin, createdTime=Tue Aug 23 19:32:14 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068268, encodeId=c77320682680d, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Dec 13 09:32:14 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605349, encodeId=27e51605349c3, content=<a href='/topic/show?id=b94d1e90023' target=_blank style='color:#2F92EE;'>#TST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17900, encryptionId=b94d1e90023, topicName=TST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30e219383639, createdName=ms3153534357578991, createdTime=Thu Jul 07 02:32:14 CST 2022, time=2022-07-07, status=1, ipAttribution=)]

相关资讯

直播中:第十二届江西省心血管病高峰论坛

第十二届江西省心血管病高峰论坛-基层与胸痛论坛

防控有道,风险管理丨刘洪洋:胸痛彻背,脂降得安

河南大学淮河医院心血管内科医师刘洪洋分享了1例超高危ASCVD患者的药物及介入治疗策略。

OCC 2022:值班遇“胸痛”,快速解读D-二聚体

心内科经常要查D-二聚体,那么,D-二聚体在胸痛患者中的临床价值在哪里?

Baidu
map
Baidu
map
Baidu
map